Spectral studies of tert-butyl isothiocyanate-inactivated P450 2E1.
Inactivation of cytochrome P450 2E1 by tert-butyl isothiocyanate (tBITC) resulted in a loss in the spectrally detectable P450-reduced CO complex. The heme prosthetic group does not appear to become modified, since little loss of the heme was observed in the absolute spectra or the pyridine hemochrome spectra, or in the amount of heme recovered from HPLC analysis of the tBITC-inactivated samples. Prolonged incubations of the inactivated P450 2E1 with dithionite and CO resulted in a recovery of both the CO complex and the enzymatic activity. Inactivated samples that were first reduced with dithionite for 1 h prior to CO exposure recovered their CO spectrum to the same extent as samples not pretreated with dithionite, suggesting that the major defect was an inability of the inactivated sample to bind CO. Spectral binding studies with 4-methylpyrazole indicated that the inactivated P450 2E1 had an impaired ability to bind the substrate. Enzymatic activity could not be restored with iodosobenzene as the alternate oxidant. EPR analysis indicated that approximately 24% of the tBITC-inactivated P450 2E1 was EPR-silent. Of the remaining tBITC-inactivated P450 2E1, approximately 45% exhibited an unusual low-spin EPR signal that was attributed to the displacement of a water molecule at the sixth position of the heme by a tBITC modification to the apoprotein. ESI-LC-MS analysis of the inactivated P450 2E1 showed an increase in the mass of the apoprotein of 115 Da. In combination, the data suggest that tBITC inactivated P450 2E1 by binding to a critical active site amino acid residue(s). This modified amino acid(s) presumably acts as the sixth ligand to the heme, thereby interfering with oxygen binding and substrate binding.
Kent
U M
UM
Department of Pharmacology, The University of Michigan, Ann Arbor, Michigan 48109-0632, USA.
Roberts-Kirchhoff
E S
ES
Moon
N
N
Dunham
W R
WR
Hollenberg
P F
PF
D000818:Animals; D001665:Binding Sites / Q000187:drug effects; D002248:Carbon Monoxide / Q000378:metabolism; D002853:Chromatography, Liquid; D019392:Cytochrome P-450 CYP2E1 / Q000737:chemistry* / Q000378:metabolism; D065691:Cytochrome P-450 CYP2E1 Inhibitors; D004227:Dithionite / Q000494:pharmacology; D004578:Electron Spin Resonance Spectroscopy; D004789:Enzyme Activation / Q000187:drug effects; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D000077604:Fomepizole; D006418:Heme / Q000378:metabolism; D007462:Iodobenzenes / Q000494:pharmacology; D017879:Isothiocyanates / Q000494:pharmacology*; D009249:NADP / Q000378:metabolism; D011720:Pyrazoles / Q000378:metabolism; D011817:Rabbits; D051381:Rats; D021241:Spectrometry, Mass, Electrospray Ionization
D065691:Cytochrome P-450 CYP2E1 Inhibitors; D004791:Enzyme Inhibitors; D007462:Iodobenzenes; D017879:Isothiocyanates; D011720:Pyrazoles; D004227:Dithionite; D006418:Heme; C039156:butyl isothiocyanate; D009249:NADP; D002248:Carbon Monoxide; D000077604:Fomepizole; D019392:Cytochrome P-450 CYP2E1; C037276:iodosobenzene